Complex Regional Pain syndrome (CRPS), which is also known as “reflex sympathetic dystrophy syndrome” is an uncommon kind of chronic pain condition characterized by severe pain and inflammation. CRPS develops after an injury, stroke or surgery and the pain is associated with the severity of the initial injury. CRPS is most common in people of age group 20-35 and more common in women than men. CRPS is also observed in children due to their injuries. Excluding the severe pain the other symptoms for CRPS include swelling and stiffness in joints, changes in the growth of nails, burning sensation and skin changes in appearance and temperature. Emotional stress can also trigger CRPS and heighten the pain sensations in an individual.
The complex regional pain syndrome is basically of two types according to the National Health Service (NHS) U.K, CRPS 1 also called reflex sympathetic dystrophy, it is an unknown condition resulting from the injury of limb which can also be related to genetics hence, likely to be a hereditary disorder. CRPS 2 is an extreme severe painful response to peripheral nerve injury but the pain does not migrate from the original site of injury unlike CRPS 1. Diagnosis of CRPS depends upon the individual’s medical history and symptoms as there is no single diagnostic test for it. The incidence rates reveal that female are three times more affected than male and occurs in the age over 60. According to a study conducted in U.K, 1 in 3,800 people develop CRPS each year.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1708
The global market for CRPS is segmented on basis of treatment and distribution channel:
- Segmentation by treatment therapies of complex regional pain syndrome
- Physical Therapy
- Surgical sympathectomy
- Intrathecal drug pumps
- Spinal cord stimulation
- Segmentation by distribution channel of complex regional pain syndrome
- Research Organizations
As CRPS can begin at any age including children, 90% of CRPS occurs if enough care is not taken by an individual after any serious injury such as fractures, soft tissue injury, limb immobilization, sprains and surgical procedures. National Institutes of Health (NIH) is supporting research for CRPS on the brain and CNS by focusing on studying new approaches in treating CRPS.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1708
On the basis of region prevalence, CRPS is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
As it is one of the rare condition there is limited data available for regional market share for CRPS but there are 50% chances of multiple sclerosis (MS) patients to develop CRPS and currently North America is one of the leading region in terms of market share followed by Europe and Asia pacific.
Some of the key market players of the complex regional pain syndrome market include Mallinckrodt Pharmaceutical, GlaxoSmithKline plc., Mylan N.V., Teva Pharmaceutical Industries Ltd., AbbVie, ACTAVIS, Zydus Pharmaceuticals, Inc., Sandoz, and Janssen Global Services, LLC..